RU2016133022A - Средство для профилактики и/или терапии ретинального воспаления - Google Patents

Средство для профилактики и/или терапии ретинального воспаления Download PDF

Info

Publication number
RU2016133022A
RU2016133022A RU2016133022A RU2016133022A RU2016133022A RU 2016133022 A RU2016133022 A RU 2016133022A RU 2016133022 A RU2016133022 A RU 2016133022A RU 2016133022 A RU2016133022 A RU 2016133022A RU 2016133022 A RU2016133022 A RU 2016133022A
Authority
RU
Russia
Prior art keywords
inhibitor
therapy
prevention
inflammation
retinal inflammation
Prior art date
Application number
RU2016133022A
Other languages
English (en)
Inventor
Флориан СЕНЛО
Ксавье ЖИЛОНО
Оливье ЛЕВИ
Жозе-Алан САЕЛЬ
Original Assignee
Юниверсите Пьер Э Мари Кюри-Пари 6 (Upmc)
Сентр Насьонал Де Ла Решерш Сентифик (Снрс)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49998095&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2016133022(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Юниверсите Пьер Э Мари Кюри-Пари 6 (Upmc), Сентр Насьонал Де Ла Решерш Сентифик (Снрс) filed Critical Юниверсите Пьер Э Мари Кюри-Пари 6 (Upmc)
Publication of RU2016133022A publication Critical patent/RU2016133022A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/204—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (5)

1. Ингибитор ИЛ-6, предназначенный для использования в лечении ретинального воспаления.
2. Ингибитор ИЛ-6 по п. 1, при этом указанное воспаление обусловлено возрастной дегенерацией макулы или пигментным ретинитом.
3. Ингибитор ИЛ-6 по п. 1 или 2, который представляет собой (i) антагонист активности ИЛ-6, такой, как антитело, распознающее ИЛ-6, растворимый рецептор ИЛ-6 или ингибитор трансляции ИЛ-6 или (ii) антагонист рецептора ИЛ-6, такой, как антитело, распознающее ИЛ-6Р или ИЛ-6Р-связывающий пептид.
4. Ингибитор ИЛ-6 по любому из пп. 1-3, который вводится интраокулярно, предпочтительно, посредством интравитреальной инъекции, или применяется местно путем глазной аппликации.
5. Ингибитор ИЛ-6 по любому из пп. 1-4, который содержится в концентрации от 5 мг/мл до 500 мг/мл.
RU2016133022A 2014-01-22 2015-01-22 Средство для профилактики и/или терапии ретинального воспаления RU2016133022A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP141521893.8 2014-01-22
EP14152189.8A EP2898896A1 (en) 2014-01-22 2014-01-22 Agents for use in the treatment of retinal inflammation
PCT/EP2015/051293 WO2015110556A1 (en) 2014-01-22 2015-01-22 Agents for use in the treatment of retinal inflammation

Publications (1)

Publication Number Publication Date
RU2016133022A true RU2016133022A (ru) 2018-02-26

Family

ID=49998095

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016133022A RU2016133022A (ru) 2014-01-22 2015-01-22 Средство для профилактики и/или терапии ретинального воспаления

Country Status (12)

Country Link
US (1) US10519232B2 (ru)
EP (2) EP2898896A1 (ru)
JP (1) JP6689484B2 (ru)
KR (1) KR102379006B1 (ru)
AU (1) AU2015208105A1 (ru)
BR (1) BR112016016901A2 (ru)
CA (1) CA2937591C (ru)
IL (1) IL246855A0 (ru)
MX (1) MX2016009600A (ru)
RU (1) RU2016133022A (ru)
SG (1) SG11201605919YA (ru)
WO (1) WO2015110556A1 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11072661B2 (en) 2015-12-23 2021-07-27 Sorbonne Universite Agents that inhibit the binding of CFH to CD11 b/CD18 and uses thereof
ITUB20169937A1 (it) 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
EP3419599A4 (en) * 2016-02-23 2019-09-11 Sesen Bio, Inc. IL-6 ANTAGONIST FORMULATIONS AND USE THEREOF
EP3454884B1 (en) * 2016-05-10 2023-07-12 Sorbonne Université Agents that activate cd47 and their use in the treatment of inflammation
IL301762A (en) * 2020-10-07 2023-05-01 Line 6 Biotechnology Inc Methods and materials for the treatment of eye diseases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2914672B2 (ja) 1989-01-17 1999-07-05 中外製薬株式会社 Ｂｓｆ▲下２▼アンタゴニスト
US5210075A (en) 1990-02-16 1993-05-11 Tanabe Seiyaku Co., Ltd. Interleukin 6 antagonist peptides
AU668349B2 (en) 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
JPH07324097A (ja) 1994-05-30 1995-12-12 Daicel Chem Ind Ltd インターロイキン６拮抗剤、及びペプチド類または医薬として許容されるその塩類
IT1274350B (it) 1994-12-06 1997-07-17 Angeletti P Ist Richerche Bio Antagonisti di interleuchina-6(il-6) che consistono di forme solubili del ricettore alfa di il-6, mutate nell'interfaccia che si lega a gp 130
IT1274782B (it) 1994-12-14 1997-07-24 Angeletti P Ist Richerche Bio Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
JPH08311098A (ja) 1995-05-22 1996-11-26 Daicel Chem Ind Ltd 新規ペプチド類およびそれを含有するインターロイキン６拮抗剤
US6001962A (en) 1996-11-15 1999-12-14 The Regents Of The University Of California Modified Fas ligands
ES2306515T3 (es) 1998-06-18 2008-11-01 Imed Ab Peptidos fas y anticuerpos para la modulacion de la apoptosis.
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
CA2637917C (en) 2006-01-27 2015-11-24 Keio University Therapeutic agents for diseases involving choroidal neovascularization
WO2008105408A1 (ja) * 2007-02-26 2008-09-04 Santen Pharmaceutical Co., Ltd. ウレイド基とアミノカルボニル基を置換基として有する新規ピロール誘導体
EP2174667B1 (en) * 2007-07-26 2017-01-04 Osaka University Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient
US20090082470A1 (en) 2007-09-24 2009-03-26 Rafal Farjo Stat3 inhibiting compositions and methods
WO2010024227A1 (ja) * 2008-08-25 2010-03-04 参天製薬株式会社 ウレイド基、アミノカルボニル基及び置換基を有してもよい二環式基を置換基として有する新規ピロール誘導体
CA2855941A1 (en) * 2011-11-14 2013-05-23 Advanced Cell Technology, Inc. Pharmaceutical preparations of human rpe cells and uses thereof
US20150051212A1 (en) 2012-03-28 2015-02-19 Regenerative Research Foundation Compositions And Methods For Inhibiting Drusen
CA2886987C (en) * 2012-11-08 2022-07-12 Eleven Biotherapeutics, Inc. Il-6 antagonists and uses thereof

Also Published As

Publication number Publication date
MX2016009600A (es) 2017-02-13
EP3096781B1 (en) 2022-11-02
US10519232B2 (en) 2019-12-31
AU2015208105A1 (en) 2016-08-04
EP2898896A1 (en) 2015-07-29
EP3096781A1 (en) 2016-11-30
JP2017505303A (ja) 2017-02-16
KR20160106667A (ko) 2016-09-12
BR112016016901A2 (pt) 2018-03-20
CA2937591C (en) 2022-09-06
CA2937591A1 (en) 2015-07-30
WO2015110556A1 (en) 2015-07-30
IL246855A0 (en) 2016-08-31
SG11201605919YA (en) 2016-08-30
KR102379006B1 (ko) 2022-03-28
US20160340424A1 (en) 2016-11-24
JP6689484B2 (ja) 2020-04-28

Similar Documents

Publication Publication Date Title
EA201890159A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ ГЕМАТОЛОГИЧЕСКОГО ЗЛОКАЧЕСТВЕННОГО НОВООБРАЗОВАНИЯ С ПОМОЩЬЮ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EA201990019A1 (ru) Соединения и композиции для подавления активности shp2
EA201890146A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ СОЛИДНЫХ ОПУХОЛЕЙ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ ИНГИБИТОРОМ mTOR В ВИДЕ НАНОЧАСТИЦ
EP4276114A3 (en) Cd20 binding single domain antibodies
BR112017005736A2 (pt) macrociclos peptidomiméticos e formulações dos mesmos
EA201892207A1 (ru) Индолкарбоксамидные соединения
EP4218816A3 (en) Pharmaceutical composition for use in prevention and/or treatment of disease that develops or progresses as a result of decrease or loss of activity of blood coagulation factor viii and/or activated blood coagulation factor viii
RU2016133022A (ru) Средство для профилактики и/или терапии ретинального воспаления
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
WO2015095819A3 (en) Cancer treatment using combinations of erk and raf inhibitors
EA202091514A1 (ru) СПОСОБЫ ЛЕЧЕНИЯ РАКА ТОЛСТОЙ КИШКИ С ИСПОЛЬЗОВАНИЕМ КОМБИНИРОВАННОЙ ТЕРАПИИ НАНОЧАСТИЦАМИ С ИНГИБИТОРОМ mTOR
EA201491773A1 (ru) Лечение рассеянного склероза комбинацией лаквинимода и диметилфумарата
WO2015195848A8 (en) Ezh2 inhibitors for treating lymphoma
EA201692480A1 (ru) Фармацевтическая композиция
EA201790745A1 (ru) Трициклические соединения
WO2016133903A3 (en) Combination therapy for cancer treatment
EA201690159A1 (ru) Способы и композиции для лечения рака
PH12016502353A1 (en) Pharmaceutical composition
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
CA3010708A1 (en) Methods of administering hepcidin
EA201790870A1 (ru) Трициклические атропоизомерные соединения
EA201790427A1 (ru) Замещенные бициклические соединения
EA201792057A1 (ru) Конденсированные бициклические гетероарильные производные с активностью ингибиторов пролилгидроксилазы